Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153038 | 0.86 | IDO1 (0.41) | IDO1MTORDAOTAAR1RXRA | |
| SCHEMBL15516422 | 0.84 | ACP1 (0.41) | IDO1MTORDAOTAAR1ACP1 | |
| SCHEMBL15516391 | 0.84 | SLC13A3 (0.40) | IDO1TACR1TSHR | |
| SCHEMBL15561899 | 0.80 | IDO1 (0.48) | IDO1CES2DAOTAAR1RXRA | |
| SCHEMBL5249761 | 0.78 | IDO1 (0.56) | IDO1CES2MTORDAOTAAR1 | |
| SCHEMBL15542723 | 0.77 | ALDH1A1 (0.43) | IDO1LMNATSHRMAPT | |
| SCHEMBL128465 | 0.77 | TAAR1 (0.60) | IDO1TAAR1LMNATSHRMAPT | |
| SCHEMBL440959 | 0.76 | CES2 (0.58) | IDO1CES2LMNARXRARXRB | |
| SCHEMBL5776968 | 0.76 | IDO1 (0.54) | IDO1CES2MTORDAOTAAR1 | |
| SCHEMBL5255362 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| US-8450303-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | claimed |
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| EP-2421856-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421860-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | claimed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124112-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | claimed |
| US-20020147219-A1 | Neurokinin antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-10 | — | — | US | claimed |
| US-6441172-B1 | DI- AND TRI-SUBSTITUTED-1,4-DIAZACYCLIC COMPOUNDS | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES | 2002-08-27 | — | — | US | claimed |
| US-20020115666-A1 | Neurokinin antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | claimed |
| WO-2002032866-A1 | (4-ACYLAMINOPIPERIDIN-1-YL) ACETAMIDES AS NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | claimed |
| WO-2002032865-A1 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | claimed |
| US-6008223-A | ANTIINFLAMMATORY AGENTS FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1999-12-28 | — | — | US | claimed |
| US-5786448-A | FOR SCREENING, SYNTHESIZING PEPTIDE DERIVATIVES | TREGA BIOSCIENCES, INC. (US) | 1998-07-28 | — | — | US | claimed |
| US-5731309-A | Substituted heteroalkyleneamine neurokinin antagonists | ZENECA LIMITED (GB) | 1998-03-24 | — | — | US | claimed |
| EP-0709376-A2 | Therapeutic compounds | ZENECA LIMITED (GB) | 1996-05-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | IDO1 1554/4885CES2 39/4885MTOR 4014/4885 |
| US-20020147219-A1 | Neurokinin antagonists | TACR2, TACR1, TAC3 | IDO1 751/4885CES2 3575/4885MTOR 2784/4885 |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | IDO1 1554/4885CES2 39/4885MTOR 4014/4885 |
| US-20020115666-A1 | Neurokinin antagonists | TACR2, TACR1, NPSR1 | IDO1 952/4885CES2 4159/4885MTOR 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.